跳至主要内容
临床试验/CTRI/2022/12/048623
CTRI/2022/12/048623已完成3 期

A Multinational, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV-45779 Compared to Omalizumab (XOLAIR®) in Patients With Chronic Idiopathic Urticaria/Chronic Spontaneous Urticaria who Remain Symptomatic Despite Antihistamine (H1) Treatment

Teva Pharmaceuticals, Inc.0 个研究点目标入组 52 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
52

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Diagnosis of CIU refractory to H1 antihistamines for =3 months.

排除标准

  • Chronic urticaria with clearly defined underlying etiology
  • Other skin disease associated with itch
  • Evidence of parasitic infection on stool evaluation for ova and parasites
  • History of anaphylactic shock
  • Hypersensitivity to omalizumab or any component of the formulation
  • Required background therapy with other than protocol-defined antihistamines
  • Any medical condition that could jeopardize or would compromise the patient safety or ability to participate in this study

研究者

相似试验

进行中(未招募)
不适用
A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sclerosis (ALS).ALS-TAL-201-OL is added as an open label extension of the ALS-TAL-201 trial: A Multinational, Multicenter, Open label phase to Assess Tolerability and Safety of Talampanel 50mg tid in Subjects with Amyotrophic Lateral Sclerosis (ALS).
EUCTR2008-002062-62-BETeva Pharmaceutical Industries, Ltd540
已完成
不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery - SAVE-HIP3-I82I82
PER-079-08sanofi-aventis Recherche & Development,
进行中(未招募)
不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery - SAVE-HIP2The subjects who will participate to this clinical trial are patients undergoing Hip Fracture Surgery.MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxis
EUCTR2007-007945-11-PTsanofi-aventis recherche & développement1,000
进行中(未招募)
不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery - SAVE-HIP2The subjects who will participate to this clinical trial are patients undergoing Hip Fracture Surgery.MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxis
EUCTR2007-007945-11-BGsanofi-aventis recherche & développement1,000
已完成
不适用
A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery - SAVE-HIP2
PER-080-08sanofi-aventis Recherche & Development,